Not Medicare Enrolled
Dr. Richard Goldfarb, MD
Urology Physician · Houston, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Goldfarb from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Goldfarb?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Goldfarb
Dr. Richard Goldfarb is an urology physician in Houston, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Goldfarb performed 12,064 Medicare services across 3,402 unique beneficiaries.
Between the years covered by Open Payments, Dr. Goldfarb received a total of $8,880 from 62 pharmaceutical and/or device companies across 391 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Goldfarb is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 8% volume in TX
$8,880 industry payments
Medicare Practice Summary
Medicare Utilization ↗12,064
Medicare services
Top 8% in TX for urology physician
3,402
Unique beneficiaries
$31
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~635 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| BCG treatment for bladder cancer | 2,750 | $2 | $3 |
| Denosumab injection (Prolia/Xgeva) | 2,460 | $19 | $24 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,455 | $93 | $134 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
1,429 | $2 | $2 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
1,084 | $47 | $65 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
868 | $8 | $8 |
| Leuprolide injectable, camcevi, 1 mg | 840 | $65 | $83 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
312 | $8 | $11 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
294 | $70 | $94 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
101 | $62 | $253 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
80 | $117 | $176 |
| Bladder instillation of anti-cancer drug A procedure where an anti-cancer medication is introduced directly into the bladder. This method delivers the treatment locally to the bladder tissue. |
57 | $70 | $95 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
46 | $11 | $15 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
38 | $140 | $184 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
31 | $26 | $33 |
| Electronic assessment of bladder emptying A test that uses electronic monitoring to evaluate how well the bladder empties urine. |
29 | $8 | $15 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
27 | $103 | $250 |
| CT scan of abdomen and pelvis, without contrast A computed tomography scan that creates detailed images of the abdominal and pelvic organs. The procedure is performed without the use of intravenous contrast dye. |
27 | $85 | $116 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
23 | $26 | $35 |
| Transurethral prostate removal with electrocautery This procedure involves removing the prostate gland through the urethra using an endoscope and an electrocautery knife to control bleeding. |
22 | $574 | $794 |
| Bladder irrigation and/or instillation This procedure involves flushing the bladder with fluid to clear it or introducing medication directly into the bladder. |
20 | $63 | $79 |
| Ultrasound guidance for needle placement Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure. |
18 | $25 | $31 |
| Complete ultrasound of retroperitoneum An ultrasound examination of the structures located behind the abdominal cavity. |
15 | $49 | $103 |
| Routine 12-lead electrocardiogram (ECG) A test that records the electrical activity of the heart using at least 12 leads to produce a tracing. |
13 | $4 | $7 |
| New patient office visit, complex (60-74 min) | 13 | $179 | $227 |
| Ureteral stone crushing with stent insertion An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open. |
12 | $340 | $425 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.1% high complexity
24.5% medium
75.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,880
Total received (2018-2024)
Avg $1,269/year across 7 years
Top 22% in TX for urology physician
62
Companies
391
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,564 (96.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$316 (3.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$266
2023
$1,328
2022
$2,022
2021
$740
2020
$678
2019
$2,164
2018
$1,682
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$1,177
PFIZER INC.
$711
Janssen Biotech, Inc.
$625
BOSTON SCIENTIFIC CORPORATION
$456
Amgen Inc.
$445
Myriad Genetic Laboratories, Inc.
$431
Boston Scientific Corporation
$384
ABBVIE INC.
$376
Antares Pharma, Inc.
$325
Endo Pharmaceuticals Inc.
$288
Ferring Pharmaceuticals Inc.
$240
Myovant Sciences Inc.
$223
Progenics Pharmaceuticals, Inc.
$210
Allergan Inc.
$200
AbbVie, Inc.
$190
Bayer HealthCare Pharmaceuticals Inc.
$175
AstraZeneca Pharmaceuticals LP
$172
Dendreon Pharmaceuticals LLC
$158
Olympus America Inc.
$155
UROVANT SCIENCES INC
$149
Allergan, Inc.
$130
Retrophin, Inc.
$125
Sumitomo Pharma America, Inc.
$116
Aytu BioScience, Inc
$99
Smith+Nephew, Inc.
$97
TOLMAR Pharmaceuticals, Inc.
$97
ACCORD HEALTHCARE, INC.
$95
Tolmar, Inc.
$73
Bayer Healthcare Pharmaceuticals Inc.
$65
AbbVie Inc.
$64
Blue Earth Diagnostics Limited
$59
NeoTract Inc.
$56
Ambu Inc.
$53
Novartis Pharmaceuticals Corporation
$52
HealthTronics Stone Solutions, LLC
$49
Axonics Modulation Technologies, Inc.
$45
UroGen Pharma, Inc.
$37
Axonics, Inc.
$31
ConvaTec Inc.
$31
Acerus Pharmaceuticals Corporation
$29
Teleflex LLC
$27
Merck Sharp & Dohme Corporation
$24
Supernus Pharmaceuticals, Inc.
$24
Alafair Biosciences, Inc.
$22
Coloplast Corp
$22
ACELL, INC.
$21
Pacira Pharmaceuticals Incorporated
$21
RGH Enterprises, Inc.
$19
Provepharm Inc.
$19
DENTSPLY IH Inc.
$19
Abbott Laboratories
$19
UROGEN PHARMA, INC.
$19
Mission Pharmacal Company
$19
Baudax Bio Inc.
$18
Laborie Medical Technologies Corp.
$16
MILLICENT US INC
$16
AKRIMAX PHARMACEUTICALS, LLC
$15
BioTissue Holdings, Inc.
$14
EDAP TECHNOMED INC
$12
Renovia Inc
$12
NxThera, Inc.
$11
Travere Therapeutics, Inc.
$1
Top 3 companies account for 28.3% of total payments
Associated products mentioned in payments ›
(815) Thiola · AFINITOR · ALTIS · AMS · AMS 700 CXR RTE KIT · ANJESO · AVEED · Androgel · Axium INS DRG IPG · Axonics · Axonics r-SNM System · Axumin · BLUDIGO · BOTOX · BOTOX THERAPEUTIC · BRAC CDx · BRACANALYSIS CDX · BRACAnalysis CDx · CAMCEVI · CERVIDIL · CLENPIQ · Dornier MedTech · ELIGARD · ERLEADA · EVENITY · EXPAREL · Erleada · FEMRING · FIRMAGON · GEMTESA · GENERAL BPH · GENERAL FEMALE SUI · GENERAL - KIDNEY STONE DISEASE · GENERAL BPH · GENTLECATH · JELMYTO · KEYTRUDA · LITHOVUE · LUPRON DEPOT · LYNPARZA · Leva Pelvic Floor Trainer · LoFric · Lupron · Lupron Depot · MYRBETRIQ · Myrbetriq · NEOX · NOCDURNA · Natesto · Nubeqa · ORGOVYX · OTREXUP · Olympus Laser Devices · Otrexup · POSLUMA · PROLARIS · PROVENGE · PYLARIFY · Prolia · REZUM · Rezum · STRAVIX PL · SpaceOAR VUE System - 10mL · TOVIAZ · Thiola · ThunderBeat · UROLIFT · Uribel · UroLift · VESICARE · VersaWrap · XIAFLEX · XTANDI · XYOSTED · Xofigo · Xtandi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $74 per 100 Medicare services performed
Geographic Context
Urology physicians within 10 mi
198
Per 100K population
4.2
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | — Not enrolled | N/A |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Goldfarb is a clinical cardiology specialist, with above-average Medicare volume (top 8% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Goldfarb experienced with bcg treatment for bladder cancer?
Based on Medicare claims data, Dr. Goldfarb performed 2,750 bcg treatment for bladder cancer services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Goldfarb receive payments from pharmaceutical companies?
Yes. Dr. Goldfarb received a total of $8,880 from 62 companies across 391 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Goldfarb's costs compare to other urology physicians in Houston?
Dr. Goldfarb's average Medicare payment per service is $31. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Goldfarb) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Houston
Browse urology physicians in Houston ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in TX
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in TX
Which TX urology physicians receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology